

Accepted Manuscript

Title: The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Author: Robert Roskoski Jr.

PII: S1043-6618(18)30143-9
DOI: <https://doi.org/10.1016/j.phrs.2018.01.021>
Reference: YPHRS 3807

To appear in: *Pharmacological Research*

Received date: 28-1-2018

Accepted date: 29-1-2018



Please cite this article as: Roskoski Robert. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. *Pharmacological Research* <https://doi.org/10.1016/j.phrs.2018.01.021>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment
of neoplastic disorders

Robert Roskoski Jr.

Blue Ridge Institute for Medical Research

3754 Brevard Road, Suite 116, Box 19

Horse Shoe, North Carolina 28742-8814, United States

Phone: 1-828-891-5637

Fax: 1-828-890-8130

E-mail address: rrj@brimr.org

Chemical compounds studied in this article: Axitinib: (PubMed CID: 6450551); Dasatinib: (PubMed CID: 3062316); Imatinib (PubMed CID: 5291); Lenvatinib: (PubMed CID: 9823820); Nilotinib: (PubMed CID: 644241); Nintedanib: (PubMed CID: 9809715); Ponatinib: (PubMed CID: 24826799); Sorafenib: (PubMed CID: 216239); Sunitinib: (PubMed CID: 5329102)

Graphical Abstract

Download English Version:

<https://daneshyari.com/en/article/8536493>

Download Persian Version:

<https://daneshyari.com/article/8536493>

[Daneshyari.com](https://daneshyari.com)